Prelude Therapeutics Incorporated PRLD

$ 0.95 -1.93%

Quarterly report 2024-Q3
added 11-06-2024

Prelude Therapeutics Incorporated Balance Sheet 2011-2024 | PRLD

Annual Balance Sheet Prelude Therapeutics Incorporated

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-8.4 M	-	-	-218 M	-18.6 M	-15.6 M	-	-	-	-	-	-	-
Long Term Debt	15.4 M	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	1.48 M	1.83 M	1.74 M	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	32 K	66.4 M	36.7 M	-	-	-	-	-	-	-
Total Current Liabilities	21.8 M	21.7 M	19.2 M	11.4 M	-	-	-	-	-	-	-	-	-
Total Liabilities	40.6 M	25.1 M	19.2 M	11.4 M	71.3 M	39.1 M	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-456 M	-335 M	-219 M	-107 M	-50.5 M	-22.9 M	-	-	-	-	-	-	-
Total Assets	278 M	220 M	305 M	224 M	21.9 M	16.4 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	25.3 M	30.6 M	31.8 M	218 M	-	-	-	-	-	-	-	-	-
Book Value	237 M	195 M	286 M	212 M	-49.4 M	-22.7 M	-	-	-	-	-	-	-
Total Shareholders Equity	237 M	195 M	286 M	212 M	-49.4 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Prelude Therapeutics Incorporated

	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	15.4 M	15.5 M	15.5 M	-	-	-	-	-	-	390 K	-	312 K	543 K	840 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	40.8 M	42 M	36.4 M	20.3 M	18.6 M	23 M	-	24.9 M	18.2 M	18.9 M	19.2 M	20 M	15.2 M	13.3 M	11.4 M	11.4 M	11.4 M	11.4 M	4.84 M	4.84 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-555 M	-523 M	-488 M	-423 M	-393 M	-362 M	-	-306 M	-276 M	-249 M	-219 M	-186 M	-156 M	-129 M	-107 M	-107 M	-107 M	-107 M	-50.5 M	-50.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	197 M	224 M	247 M	259 M	281 M	198 M	-	242 M	259 M	281 M	305 M	331 M	350 M	370 M	224 M	224 M	224 M	224 M	21.9 M	21.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	11.1 M	27.8 M	24.7 M	15.9 M	26.4 M	18.2 M	-	52 M	50.7 M	51.6 M	31.8 M	61.4 M	343 M	363 M	218 M	218 M	218 M	218 M	18.9 M	18.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	156 M	182 M	211 M	238 M	262 M	175 M	-	217 M	241 M	262 M	286 M	311 M	334 M	357 M	212 M	212 M	212 M	212 M	17 M	17 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	156 M	182 M	211 M	238 M	262 M	175 M	-	217 M	241 M	262 M	286 M	311 M	334 M	357 M	212 M	212 M	212 M	212 M	-49.4 M	-49.4 M	-33.3 M	-27.9 M	-22.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency